Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Bethesda, MD

153 studies for Breast Cancer are recruiting at 364 sites within 50 miles of Bethesda, Maryland, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Bethesda.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Bethesda

Showing the 50 nearest of 153 studies.
  1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Walter Reed National Military Medical Center (Bethesda, MD); Kaiser Permanente - Kensington Medical Center (Kensington, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    25 sites within 50 mi
  2. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Walter Reed National Military Medical Center (Bethesda, MD); Kaiser Permanente Tysons Corner Medical Center (McLean, VA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    21 sites within 50 mi
  3. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Walter Reed National Military Medical Center (Bethesda, MD); MedStar Georgetown University Hospital (Washington D.C., DC)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 50 mi
  4. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Walter Reed National Military Medical Center (Bethesda, MD); MedStar Georgetown University Hospital (Washington D.C., DC)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 50 mi
  5. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    NCT03053193

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Maryland Oncology Hematology - Bethesda (Bethesda, MD); Maryland Oncology Hematology, PA (Silver Spring, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  6. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    NCT06401421

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: The Center for Cancer and Blood Disorders - Bethesda (Bethesda, MD); Holy Cross Hospital - Silver Spring (Silver Spring, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  7. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: National Institutes of Health Clinical Center (Bethesda, MD); Walter Reed National Military Medical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  8. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest sites: Massive Bio SYNERGY-AI site (Bethesda, MD); Massive Bio SYNERGY-AI site (Silver Spring, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  9. The Vanguard Study: Testing a New Way to Screen for Cancer

    NCT06995898

    • Interventional
    • Ages 45 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Walter Reed National Military Medical Center (Bethesda, MD); Inova Fair Oaks Hospital (Fairfax, VA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  10. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    NCT07174336

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: American Oncology Partners, PA (Bethesda, MD); MedStar Washington Hospital Center (Washington D.C., DC)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  11. Collection of Blood From Patients With Cancer

    NCT00034216

    • Observational
    • Ages 18 years and older
    • Sex: All
    • Accepts healthy volunteers

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  12. Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

    NCT00451022

    • Observational
    • Ages 18 years and older
    • Sex: All
    • Accepts healthy volunteers

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  13. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

    NCT01174121

    • Phase 2
    • Ages 18 to 72 years
    • Sex: All

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  14. Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

    NCT01441089

    • Observational
    • Ages 3 years and older
    • Sex: All

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  15. Genomic Services Research Program

    NCT02595957

    • Observational
    • Ages 1 month to 105 years
    • Sex: All

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  16. Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

    NCT02830724

    • Phase 1/2
    • Ages 18 to 72 years
    • Sex: All

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  17. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

    NCT03412877

    • Phase 2
    • Ages 18 to 72 years
    • Sex: All

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  18. Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

    NCT04222413

    • Phase 1
    • Ages 12 to 120 years
    • Sex: All

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  19. Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

    NCT05660083

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: National Institute of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  20. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    NCT06072612

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A. (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  21. A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

    NCT07067138

    • Interventional
    • Ages 18 to 120 years
    • Sex: All

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  22. Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

    NCT07619534

    • Observational
    • Ages 18 to 120 years
    • Sex: All

    Nearest site: National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  23. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    NCT06841354

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Holy Cross Hospital ( Site 0091) (Silver Spring, MD); Washington Hospital Center ( Site 0098) (Washington D.C., DC)

    Distance to nearest recruiting site
    ~4 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  24. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    NCT06312176

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Holy Cross Hospital ( Site 0073) (Silver Spring, MD); Inova Schar Cancer Institute ( Site 0025) (Fairfax, VA)

    Distance to nearest recruiting site
    ~4 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  25. Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

    NCT05827081

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Maryland Oncology Hematology P A (Silver Spring, MD); Mercy Medical Center (Baltimore, MD)

    Distance to nearest recruiting site
    ~4 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    NCT06380751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Research Site (Silver Spring, MD)

    Distance to nearest recruiting site
    ~4 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  27. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    NCT06393374

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Holy Cross Hospital ( Site 0069) (Silver Spring, MD)

    Distance to nearest recruiting site
    ~4 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All

    Nearest sites: Kaiser Permanente Tysons Corner Medical Center (McLean, VA); Kaiser Permanente-Capitol Hill Medical Center (Washington D.C., DC)

    Distance to nearest recruiting site
    ~5 mi (city-level)
    Recruiting sites
    24 sites within 50 mi
  29. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: George Washington University Medical Center (Washington D.C., DC); MedStar Georgetown University Hospital (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  30. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Georgetown University Medical Center (Washington D.C., DC); MedStar Washington Hospital Center (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  31. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: MedStar Georgetown University Hospital (Washington D.C., DC); MedStar Washington Hospital Center (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  32. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sibley Memorial Hospital (Washington D.C., DC); UM Baltimore Washington Medical Center/Tate Cancer Center (Glen Burnie, MD)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  33. Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

    NCT06500481

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sibley Memorial Hospital (Washington D.C., DC); Inova Alexandria Hospital (Alexandria, VA)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  34. The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

    NCT05780814

    • Interventional
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Sibley Memorial Hospital (Washington D.C., DC); Johns Hopkins Bayview (Baltimore, MD)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  35. QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

    NCT06551116

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Georgetown University - Lombardi CCC (Washington D.C., DC); MedStar Washington Hospital Center (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  36. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    NCT05232916

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Johns Hopkins Medicine - Kimmel Cancer Center-Sibley Memorial Hospital (Washington D.C., DC); Virginia Cancer Specialists (Fairfax, VA)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  37. A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

    NCT06435429

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Medstar Georgetown University Hospital (Washington D.C., DC); Washington Cancer Center (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  38. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Georgetown University Medical Center (Washington D.C., DC); Virginia Cancer Specialists, PC (Fairfax, VA)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  39. RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

    NCT05256745

    • Phase 1/2
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Georgetown Lombardi Comprehensive Cancer Center (Washington D.C., DC); Medstar Washington Hospital Center (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  40. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    NCT05315700

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Georgetown University (Washington D.C., DC); Next Oncology (Fairfax, VA)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  41. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    NCT05894239

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Georgetown Uni Hospital (Washington D.C., DC); Medstar Research Institute (Hyattsville, MD)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  42. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    NCT05983432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Georgetown University Medical Center (Washington D.C., DC); Virginia Cancer Specialists (Fairfax, VA)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  43. Circulating Tumor DNA

    NCT06923527

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (Washington D.C., DC); Sidney Kimmel Comprehensive Cancer Center at John Hopkins (Baltimore, MD)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  44. ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

    NCT07007559

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: The George Washington Medical facility Associates (Washington D.C., DC); Virginia Cancer Specialists (Fairfax, VA)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  45. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    NCT07182149

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Normunity Investigational Site (Washington D.C., DC); Normunity Investigational Site (Fairfax, VA)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  46. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    NCT01042379

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Georgetown University Medical Center (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. Cancer Experience Registry (CER) for Cancer Patients and Caregivers

    NCT02333604

    • Observational
    • Ages 18 years and older
    • Sex: All
    • Accepts healthy volunteers

    Nearest site: Cancer Support Community Research & Training Institute (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. Older Breast Cancer Patients: Risk for Cognitive Decline

    NCT03451383

    • Observational
    • Ages 60 to 105 years
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: Georgetown University (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

    NCT04841148

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Georgetown University (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

    NCT05130606

    • Interventional
    • Ages 18 years and older
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: Georgetown Lombardi Comprehensive Cancer Center (Washington D.C., DC)

    Distance to nearest recruiting site
    ~7 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.